Oncotype DX RS Correlation with Clinicopathologic Risk Factors and Chemotherapy: Follow up Based on TAILORx Study

Background: Oncotype DX risk score is a clinically validated prognostic and predictive molecular test. It estimates the recurrence and predicts the likelihood of benefit from adjuvant chemotherapy in early ER\PR positive, node-negative breast cancer. Patients are categorized into one of three tiers based on a calculated recurrence score (RS); low (